Click here to see
the Case Study
Step 01
tHE idea
The Objective
The scientific journal editor proposes illustration services to authors who wish to publish in their peer-reviwed journal.
As scientific graphic designer, I then intervene to adapt the author's graphical abstract or figure to journal guidelines and style.
Step 02
tHE brief
Peer-reviewed journal - IF: 10.1
Journal style
Editor's guidelines include a precise format for the figure: 510.24 px x 510.24 px (formatted in cm).
Myriad Pro font is preferred and should not be smaller than 7 pt
Colors should be adapted for color-blind people:
elements that need to be identified or differentiated need to be seen by at least the most common types of color blindness (Protanopia and Deuteranopia).
A color palette has been defined by my collaborator Somersault 18:24, in agreement with the editor.
Step 03
tHE abstract
The development of graft-versus-host disease prophylaxis
Allogeneic transplantation is routinely employed as curative therapy for patients with hematologic malignancies and, increasingly, for a variety of non-malignant diseases. Overcoming the barrier of alloimmunity is fundamental to the success of allogeneic transplantation. Thus, the development of potent immunosuppressive medications was the key event leading to the routine use of transplantation for the treatment of hematologic malignancies. Methotrexate was the first widely used immunosuppressive agent, and the development of cyclosporine A in the early 1970s represented a major breakthrough in immunosuppression. Methotrexate acts as an antiproliferative agent, preventing cell cycling and division of activated T cells, while cyclosporine A acts by preventing T-cell activation and upregulation in response to inflammatory cytokines and paracrine T-cell signaling. Used individually, each provides some degree of protection against lethal acute graft-versus-host disease (GvHD), although single-agent methotrexate is associated with very modest success. Cyclosporine was noted to be more potent as post-transplant monotherapy when compared with methotrexate, leading ultimately to the clinical trial described below.
Thank you